By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697




Merck & Co.  Antifungals

Company News
SCYNEXIS, Inc. (SCYX) Receives FDA Fast Track Designation For Oral Formulation Of SCY-078 For The Treatment Of Patients With Invasive Fungal Infections 1/9/2015 7:42:58 AM
SCYNEXIS, Inc. (SCYX) Announces Appointment Of Two Seasoned Industry Professionals To Its Board Of Directors 12/4/2014 4:34:13 PM
SCYNEXIS, Inc. (SCYX) Reports Third Quarter 2014 Financial Results 11/13/2014 10:29:25 AM
SCYNEXIS, Inc. (SCYX) Enters Into Worldwide Agreement With Waterstone Pharmaceutical For The Development And Commercialization Of SCY-635 For Viral Diseases 11/3/2014 10:05:16 AM
SCYNEXIS, Inc. (SCYX) Reports Second Quarter 2014 Financial Results 8/13/2014 7:32:54 AM
SCYNEXIS, Inc. (SCYX) To Present At Canaccord Genuity Growth Conference 2014 8/6/2014 8:44:33 AM
SCYNEXIS, Inc. (SCYX) To Present At JMP Securities Healthcare Conference 6/18/2014 8:57:42 AM
SCYNEXIS, Inc. (SCYX) Provides Update On Corporate Progress And First Quarter 2014 Financial Results 6/16/2014 7:39:38 AM
After Three Delays, SCYNEXIS, Inc. (SCYX) Finally Goes IPO At $10 A Share 5/2/2014 10:51:11 AM
SCYNEXIS, Inc. Announces Launch Of Initial Public Offering Of Common Stock 3/24/2014 9:44:57 AM